BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
Portfolio Pulse from Vandana Singh
The FDA has approved BioMarin Pharmaceutical Inc's Roctavian gene therapy for adults with severe hemophilia A. This is the first approved gene therapy for severe hemophilia A in the U.S. BioMarin will continue to monitor the long-term effects of treatment with an extension study. Analysts from William Blair, Truist Securities, and Wedbush have given positive outlooks for BioMarin, with Truist Securities and Wedbush raising their price targets.
June 30, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioMarin's Roctavian has received FDA approval, marking it as the first gene therapy for severe hemophilia A in the U.S. Analysts have given positive outlooks for the company, with some raising their price targets.
The FDA approval of Roctavian is a significant milestone for BioMarin, as it is the first gene therapy for severe hemophilia A in the U.S. This approval could potentially increase the company's market share and revenues. Furthermore, positive outlooks and raised price targets from analysts indicate a positive sentiment towards the company's stock, which could drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100